← Human Trials & Peer-Reviewed Studies
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
Plain-language guide to PMID 16720661 (2006): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 16720661
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Akintoye SO et al. (8 authors)
- DOI
- 10.1210/jc.2005-2661
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
MAS is caused by sporadic, postzygotic, activating mutations in the GNAS gene, which codes for the cAMP-regulating protein, G(s)alpha (gsp oncogene).
These same mutations are found in approximately one third of the sporadic cases of acromegaly.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.
What Was Measured
The subject headings attached to it are Bone and Bones, Chromogranins, Fatigue, Fibrous Dysplasia of Bone, Fibrous Dysplasia, Polyostotic, GTP-Binding Protein alpha Subunits, Gs and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.